newswire, breaking biotechnology and pharma news

Friday, August 19, 2016

#Mining and #Biotech #Stocks Added to

#Mining and #Biotech #Stocks Added to

Mining Companies Include: TSX: $WG.TO; TSXV: $AZR.V, $CAP.V, $CVA.V, $ZFR.V, $ERA.V; OTC: $ECORF; CSE: $NSM

Point Roberts, WA, Delta BC – August 19, 2016 –, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories.  Additions within the mining sector were TSX Listed Companies.

Biotech additions include a cancer treatment company, an eye treatment company and a company that directs its research towards treatments for today’s ageing population. global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

Mining Companies Added:
Wellgreen Platinum Ltd. (TSX:WG.TO), Azarga Metals Corp (TSX:AZR.V), Castle Peak Mining Ltd. (TSX:CAP.V), Cava Resources Inc. (TSX:CVA.V), Zephyr Minerals Ltd. (TSX:ZFR.V), ELCORA ADVANCED MATERIALS CORP. (TSX:ERA.V; OTCQB: ECORF) and Northern Sphere Mining Corp. (CSE: NSM) 

Biotech Companies Added:
Kura Oncology Inc. (NasdaqGS:KURA) is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, as well as an inhibitor of the menin-MLL interaction.

Nymox Pharmaceutical Corp. (NasdaqCM:NYMX) specializes in the research and development of novel drugs and diagnostic products for the aging population. Nymox's lead drug candidate is NX-1207, a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH). NX-1207 is currently in Phase 3 trials in the United States. Nymox has other new drug products in development in the fields of cancer, infectious disease, neurodegenerative diseases, and other areas.

Ocular Therapeutix Inc. (NasdaqGM:OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™ (dexamethasone insert), is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for dry eye disease. A third Phase 3 clinical trial is being conducted for post-surgical ocular inflammation and pain. For glaucoma and ocular hypertension, the Company plans to initiate the first of two OTX-TP (sustained release travoprost) Phase 3 clinical trials in the third quarter of 2016. Ocular Therapeutix is also evaluating sustained-release injectable drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

About - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow on Twitter!/Investorideas
Follow on Facebook

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies:

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:  Global investors must adhere to regulations of each country.


No comments:

Post a Comment